Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

arVax(TM). The objective of the Phase II study was to evaluate safety, tolerability and immunogenicity of SparVax(TM) and to compare it to the licensed vaccine, BioThrax(R), which was administered in accordance with the then approved vaccination route and regimen for general use in prophylaxis against anthrax. A total of 226 healthy male and female volunteers, age 18-55, were enrolled in the trial which was conducted at 16 sites in the United States.

The subjects were randomized to receive either three doses of BioThrax(R) or SparVax(TM) (at one of two dose levels followed by an antigenic challenge dose, i.e., a dose to show that the initial series of doses adequately "primed" the immune system to respond to natural infection by producing antibody due to immunologic memory.) The three dose groups were: 50 Microgram SparVax on Days 0, 28 and 56 (n = 91); 100 Microgram SparVax on Days 0, 28 and 56 (n = 92), and; 0.5 mL BioThrax(R) on Days 0, 14, and 28 (n = 43). At day 182, subjects receiving SparVax(TM) were re-randomized to a challenge at the original dose, on either day 182 or 364. The antigenic challenge dose (50 or 100 Microgram) each subject received was the same as the dose assigned to that subject during the initial vaccination schedule. Safety and immunogenicity were assessed throughout the study.

BioThrax(R) subjects were allowed to complete the full course of treatment, but data were not collected from these subjects after Day 70. Subjects who continued in the study were followed up for 18 months (Day 546) from the original vaccine dose.

Study results showed that there were an increased proportion of individuals experiencing injection site pain in the BioThrax(R) group as compared to the SparVax(TM) groups at both dose levels. There were no notable differences between the SparVax(TM) groups and the BioThrax(R) group regarding safety laboratory values, vital signs and ECG results. Additionally, in th
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at the Citi ... May 26, 2010 at 3:00 p.m. ET / 12:00 ... Amylin Pharmaceuticals, will provide a corporate overview. , ... The presentation will be webcast live through the "Investors" section of Amylin,s ...
... May 19 After delivering a unanimous verdict against ... $3.36 million in compensatory damages yesterday, a New ... medicine.  Announcing the amount of punitive damages to be awarded, the ... for the gender discrimination it inflicted on 5,600 working women ...
... 19 Hothead Technologies, Inc. and Sivix Logistics ... computing fob and associated sensor monitoring module to its ... based upon the H.O.T.™ System, a patent-pending system that ... an athlete, firefighter, soldier, or other personnel and collects ...
Cached Biology Technology:Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference 2Novartis Class Awarded $250 Million in Punitive Damages 2Novartis Class Awarded $250 Million in Punitive Damages 3Novartis Class Awarded $250 Million in Punitive Damages 4Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 2Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 3
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... in cocoa has been developed by a team of ... Incorporated, and recently published in the Journal of ... in flavanol chemistry and analytics, the method identifies and ... cocoa and chocolate products. Foods rich in flavanols are ...
... /PRNewswire-iReach/  -- Global Information Inc. is announces limited ... three important Boston healthcare conferences: Next-Gen ... the rapidly maturing kinase inhibitors field will gather to ... the Next-Gen Kinase Inhibitors Conference in Cambridge, ...
... SAN DIEGOObstructive sleep apnea (OSA) is a disorder in which there ... effort to breathe. OSA is estimated to affect 1 in 5 ... in a landmark study which found that middle-age and older men ... risk of stroke and death. While a link between OSA and ...
Cached Biology News:Scientists advance field of research with publication of newly validated method for analyzing flavanols in cocoa 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3Obstructive sleep apnea's damage evident after 1 month 2
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... filters suitable for use in the Microsart e.motion ... each filter, in a specially designed individual package ... of the band of membrane filter units ensures ... shape of the sealed band guarantees uniform dispensing ...
...
... VSR-50 Variable Speed Rocker, with 12" x ... with 12" x 14" table; 220V. The ... of equipment for any lab. The VSR-50 provides ... allows for a gentle to vigourous movement. This ...
Biology Products: